Open AccessThis article is
- freely available
Marine-Derived Angiogenesis Inhibitors for Cancer Therapy
Division of Antitumor Pharmacology, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 Zu Chong Zhi Road, Zhangjiang Hi-Tech Park, Shanghai 201203, China
* Author to whom correspondence should be addressed.
Received: 4 February 2013; in revised form: 25 February 2013 / Accepted: 1 March 2013 / Published: 15 March 2013
Abstract: Angiogenesis inhibitors have been successfully used for cancer therapy in the clinic. Many marine-derived natural products and their analogues have been reported to show antiangiogenic activities. Compared with the drugs in the clinic, these agents display interesting characteristics, including diverse sources, unique chemical structures, special modes of action, and distinct activity and toxicity profiles. This review will first provide an overview of the current marine-derived angiogenesis inhibitors based on their primary targets and/or mechanisms of action. Then, the marine-derived antiangiogenic protein kinase inhibitors will be focused on. And finally, the clinical trials of the marine-derived antiangiogenic agents will be discussed, with special emphasis on their application potentials, problems and possible coping strategies in their future development as anticancer drugs.
Keywords: marine natural products; angiogenesis; protein kinase; cancer therapy
Citations to this Article
Cite This Article
MDPI and ACS Style
Wang, Y.-Q.; Miao, Z.-H. Marine-Derived Angiogenesis Inhibitors for Cancer Therapy. Mar. Drugs 2013, 11, 903-933.
Wang Y-Q, Miao Z-H. Marine-Derived Angiogenesis Inhibitors for Cancer Therapy. Marine Drugs. 2013; 11(3):903-933.
Wang, Ying-Qing; Miao, Ze-Hong. 2013. "Marine-Derived Angiogenesis Inhibitors for Cancer Therapy." Mar. Drugs 11, no. 3: 903-933.